Roivant's brepocitinib meets all Phase 3 endpoints in uveitis
Roivant Sciences and its subsidiary Priovant Therapeutics have reported positive topline results from the CLARITY-1 and CLARITY-2 Phase 3 trials of brepocitinib in non-infectious uveitis (NIU), with the TYK2/JAK1 inhibitor meeting the primary endpoint and every pre-specified key secondary endpoint in both studies. Priovant said it intends to file a supplemental New Drug Application with the FDA in the first half of 2027.
The two identical, 48-week double-masked trials enrolled 371 patients in total, randomised 1:1 to once-daily brepocitinib 45 mg or placebo. All participants also received an eight-week oral corticosteroid regimen with a mandatory taper to zero from week two. The primary endpoint was time to treatment failure, measured from week six through week 48.
Trial results
Median time to treatment failure exceeded 48 weeks in the brepocitinib arms of both studies, compared with approximately 12 weeks in each placebo arm (p less than 0.0001 in both). The hazard ratios for treatment failure were 0.27 (95% CI 0.17 to 0.43) in CLARITY-1 and 0.22 (95% CI 0.14 to 0.34) in CLARITY-2, representing a reduction in failure risk of roughly 73% and 78% respectively. Pooled across both studies, 62% of brepocitinib patients achieved steroid-free quiescence at week 48 versus 20% on placebo. Among patients who entered with macular oedema, 42% of eyes in the brepocitinib group achieved resolution by week 48, compared with 4.8% on placebo. Statistically significant improvements were also recorded in chorioretinal vascular leakage on fluorescein angiography and in patient-reported visual functioning on the NEI VFQ-25 scale.
Quan Dong Nguyen, Professor of Ophthalmology at the Byers Eye Institute and Stanford University School of Medicine and President of the International Ocular Inflammation Society, described the results as capable of redefining expectations for the field: "Even with a much faster taper of oral prednisone, patients treated with brepocitinib in CLARITY demonstrated highly differentiated benefits across the primary and all key secondary endpoints."
Safety findings were consistent with the established brepocitinib profile. Most adverse events were mild or moderate, and only 3% of participants discontinued treatment due to an adverse event. No new safety signals were identified.
Market context and regulatory read-across
Brepocitinib is already commercially available in the United States under the brand name LISRAYA for adults with dermatomyositis, having received FDA approval in that indication. The NIU filing would represent a second rare-disease immunology indication for the molecule, extending the commercial platform Priovant is building around TYK2/JAK1 inhibition.
NIU is estimated to affect between 70,000 and 190,000 adults in the United States and is among the leading causes of blindness in the working-age population. Current systemic options are largely limited to corticosteroids and off-label immunosuppressants; no targeted oral therapy is approved specifically for NIU in the US. That regulatory gap makes the competitive landscape relatively open for a first approved agent, though the FDA's review of an sNDA will scrutinise the steroid-sparing design against historical control benchmarks and assess the safety profile of long-term JAK pathway inhibition, an area of ongoing regulatory attention following post-marketing cardiovascular and malignancy data from other JAK inhibitors in rheumatological indications.
Roivant's broader pipeline also includes IMVT-1402, a monoclonal antibody targeting FcRn in IgG-mediated autoimmune disease, and mosliciguat for pulmonary hypertension. Investors will be watching whether the CLARITY data are sufficient to support a priority review voucher application given the rare-disease prevalence estimates, and whether the full dataset presented at a medical conference confirms the strong effect sizes seen in the topline release.